{"id":9097,"date":"2019-10-17T11:00:00","date_gmt":"2019-10-17T09:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/"},"modified":"2019-10-17T11:00:00","modified_gmt":"2019-10-17T09:00:00","slug":"valberedningen-i-irlab-utsedd","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/valberedningen-i-irlab-utsedd\/","title":{"rendered":"Valberedningen i IRLAB utsedd"},"content":{"rendered":"<p>[mfn_before_post]<\/p>\n<div class=\"mfn-preamble\"><strong>IRLAB meddelade idag att inf\u00f6r \u00e5rsst\u00e4mman 2020 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Daniel Johnsson och Clas Sonesson samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans cirka 57 procent av aktier och r\u00f6ster i bolaget.<\/strong><\/div>\n<p><span>Enligt den instruktion f\u00f6r valberedning i IRLAB Therapeutics AB som antogs p\u00e5 \u00e5rsst\u00e4mman den 25 april 2019 ska valberedningen, ut\u00f6ver styrelsens ordf\u00f6rande, best\u00e5 av representanter f\u00f6r de tre st\u00f6rsta aktie\u00e4garna, eller \u00e4gargrupperna, per den 31 augusti.<\/span><\/p>\n<p><span>Efter att de tre st\u00f6rsta \u00e4garna eller \u00e4gargrupperna utsett sina representanter har valberedningen haft sitt f\u00f6rsta m\u00f6te. Valberedningen best\u00e5r av f\u00f6ljande ledam\u00f6ter:<\/span><\/p>\n<ul>\n<li>\u00a0<span>Bo Rydlinger, valberedningens ordf\u00f6rande, bakgrund fr\u00e5n bank- och investeringsverksamhet, utsedd av en \u00e4gargrupp som representerar cirka 21 procent av aktier och r\u00f6ster;<\/span><\/li>\n<li>\u00a0<span>Daniel Johnsson, entrepren\u00f6r, bolagsutvecklare och investerare, utsedd av en \u00e4gargrupp som representerar cirka 24 procent av aktier och r\u00f6ster;<\/span><\/li>\n<li>\u00a0<span>Clas Sonesson, forskningschef (CSO) p\u00e5 IRLAB och en av IRLAB:s grundare. Utsedd av en \u00e4gargrupp best\u00e5ende av bolagets grundare som representerar cirka 13 procent av aktier och r\u00f6ster; samt<\/span><\/li>\n<li>\u00a0<span>Anders Vedin, styrelseordf\u00f6rande i IRLAB Therapeutics AB.<\/span><\/li>\n<\/ul>\n<p><span>Information om valberedningens arbete samt instruktionen till valberedningen \u00e5terfinns p\u00e5 bolagets hemsida under sektionen f\u00f6r bolagsstyrning (corporate governance). Valberedningens f\u00f6rslag kommer att presenteras i kallelsen till \u00e5rsst\u00e4mman 2020 samt p\u00e5 bolagets hemsida \u2013 irlab.se.<\/span><\/p>\n<p><span>Aktie\u00e4gare som vill l\u00e4mna f\u00f6rslag till valberedningen kan kontakta valberedningen p\u00e5 bolagets adress eller e-post &#8211; info@irlab.se. F\u00f6r att ge valberedningen m\u00f6jlighet att beakta ett f\u00f6rslag m\u00e5ste det ha inkommit till valberedningen i god tid f\u00f6re \u00e5rsst\u00e4mman, dock senast den 31 januari 2020.<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><strong>F\u00f6r vidare information<\/strong><\/p>\n<p>Bo Rydlinger, valberedningens ordf\u00f6rande \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<br \/>Tel: +46 701 495 405<br \/>E-post: <a href=\"mailto:bo.rydlinger@sofama.se\" rel=\"nofollow\">bo.rydlinger@sofama.se<\/a><\/p>\n<p>Anders Vedin, styrelseordf\u00f6rande<br \/>Tel: +46 70 876 15 70<br \/>E-post: <a href=\"mailto:anders.vedin@irlab.se\" rel=\"nofollow\">anders.vedin@irlab.se<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong>Om IRLAB<\/strong><\/p>\n<p>IRLAB \u00e4r ett svenskt biotechbolag fokuserat p\u00e5 Parkinsons sjukdom. Bolagets kliniska Fas II-kandidater, IRL752 och IRL790, \u00e4mnar behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinsons sjukdom: ofrivilliga r\u00f6relser (LIDs), psykos och demens. Genom den propriet\u00e4ra forskningsplattformen ISP (Integrative Screening Process) uppt\u00e4cker och utvecklar IRLAB l\u00e4kemedelskandidater f\u00f6r sjukdomar relaterade till det centrala nervsystemet (CNS) d\u00e4r stora v\u00e4xande medicinska behov f\u00f6religger. F\u00f6rutom de kliniska kandidaterna har ISP-plattformen dessutom genererat flera CNS-program som nu \u00e4r i preklinisk fas. IRLAB:s Certified Adviser p\u00e5 Nasdaq First North \u00e4r FNCA Sweden AB, info@fnca.se, 08-528 00 399. Mer information p\u00e5 <a href=\"http:\/\/www.irlab.se\/\" rel=\"nofollow\">www.irlab.se<\/a>.<\/p>\n<\/div>\n<p>[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRLAB meddelade idag att inf\u00f6r \u00e5rsst\u00e4mman 2020 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Daniel Johnsson och Clas Sonesson samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans cirka 57 procent av aktier och r\u00f6ster i bolaget.<\/p>\n","protected":false},"template":"","class_list":["post-9097","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-ci-nomination_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Valberedningen i IRLAB utsedd - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedningen i IRLAB utsedd - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att inf\u00f6r \u00e5rsst\u00e4mman 2020 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Daniel Johnsson och Clas Sonesson samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans cirka 57 procent av aktier och r\u00f6ster i bolaget.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/\",\"name\":\"Valberedningen i IRLAB utsedd - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2019-10-17T09:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedningen i IRLAB utsedd\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedningen i IRLAB utsedd - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedningen i IRLAB utsedd - IRLAB","og_description":"IRLAB meddelade idag att inf\u00f6r \u00e5rsst\u00e4mman 2020 har bolagets tre st\u00f6rsta \u00e4gare, eller \u00e4gargrupper, utsett ledam\u00f6ter till valberedningen. I valberedningen ing\u00e5r Bo Rydlinger, Daniel Johnsson och Clas Sonesson samt styrelsens ordf\u00f6rande Anders Vedin. Valberedningen representerar tillsammans cirka 57 procent av aktier och r\u00f6ster i bolaget.","og_url":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/","url":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/","name":"Valberedningen i IRLAB utsedd - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2019-10-17T09:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/valberedningen-i-irlab-utsedd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"Valberedningen i IRLAB utsedd"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}